258 related articles for article (PubMed ID: 25814644)
1. Nonbiased Molecular Screening Identifies Novel Molecular Regulators of Fibrogenic and Proliferative Signaling in Myxomatous Mitral Valve Disease.
Thalji NM; Hagler MA; Zhang H; Casaclang-Verzosa G; Nair AA; Suri RM; Miller JD
Circ Cardiovasc Genet; 2015 Jun; 8(3):516-28. PubMed ID: 25814644
[TBL] [Abstract][Full Text] [Related]
2. TGF-β signalling and reactive oxygen species drive fibrosis and matrix remodelling in myxomatous mitral valves.
Hagler MA; Hadley TM; Zhang H; Mehra K; Roos CM; Schaff HV; Suri RM; Miller JD
Cardiovasc Res; 2013 Jul; 99(1):175-84. PubMed ID: 23554457
[TBL] [Abstract][Full Text] [Related]
3. Loss of Axin2 results in impaired heart valve maturation and subsequent myxomatous valve disease.
Hulin A; Moore V; James JM; Yutzey KE
Cardiovasc Res; 2017 Jan; 113(1):40-51. PubMed ID: 28069701
[TBL] [Abstract][Full Text] [Related]
4. Loss of β-catenin promotes chondrogenic differentiation of aortic valve interstitial cells.
Fang M; Alfieri CM; Hulin A; Conway SJ; Yutzey KE
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2601-8. PubMed ID: 25341799
[TBL] [Abstract][Full Text] [Related]
5. Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers.
Geirsson A; Singh M; Ali R; Abbas H; Li W; Sanchez JA; Hashim S; Tellides G
Circulation; 2012 Sep; 126(11 Suppl 1):S189-97. PubMed ID: 22965982
[TBL] [Abstract][Full Text] [Related]
6. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation.
Caira FC; Stock SR; Gleason TG; McGee EC; Huang J; Bonow RO; Spelsberg TC; McCarthy PM; Rahimtoola SH; Rajamannan NM
J Am Coll Cardiol; 2006 Apr; 47(8):1707-12. PubMed ID: 16631011
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis and abundance of Bcl-2 family and transforming growth factor β1 signaling proteins in canine myxomatous mitral valves.
Surachetpong S; Jiranantasak T; Rungsipipat A; Orton EC
J Vet Cardiol; 2013 Sep; 15(3):171-80. PubMed ID: 23816827
[TBL] [Abstract][Full Text] [Related]
8. TGF-β mediates early angiogenesis and latent fibrosis in an Emilin1-deficient mouse model of aortic valve disease.
Munjal C; Opoka AM; Osinska H; James JF; Bressan GM; Hinton RB
Dis Model Mech; 2014 Aug; 7(8):987-96. PubMed ID: 25056700
[TBL] [Abstract][Full Text] [Related]
9. Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.
Oyama MA; Elliott C; Loughran KA; Kossar AP; Castillero E; Levy RJ; Ferrari G
Cardiovasc Pathol; 2020; 46():107196. PubMed ID: 32006823
[TBL] [Abstract][Full Text] [Related]
10. TGF-β-induced PI3K/AKT/mTOR pathway controls myofibroblast differentiation and secretory phenotype of valvular interstitial cells through the modulation of cellular senescence in a naturally occurring in vitro canine model of myxomatous mitral valve disease.
Tang Q; Markby GR; MacNair AJ; Tang K; Tkacz M; Parys M; Phadwal K; MacRae VE; Corcoran BM
Cell Prolif; 2023 Jun; 56(6):e13435. PubMed ID: 36869852
[TBL] [Abstract][Full Text] [Related]
11. Metallothionein-dependent up-regulation of TGF-β2 participates in the remodelling of the myxomatous mitral valve.
Hulin A; Deroanne CF; Lambert CA; Dumont B; Castronovo V; Defraigne JO; Nusgens BV; Radermecker MA; Colige AC
Cardiovasc Res; 2012 Mar; 93(3):480-9. PubMed ID: 22180604
[TBL] [Abstract][Full Text] [Related]
12. Autocrine serotonin and transforming growth factor beta 1 signaling mediates spontaneous myxomatous mitral valve disease.
Disatian S; Orton EC
J Heart Valve Dis; 2009 Jan; 18(1):44-51. PubMed ID: 19301552
[TBL] [Abstract][Full Text] [Related]
13. Human myxomatous mitral valve prolapse: role of bone morphogenetic protein 4 in valvular interstitial cell activation.
Sainger R; Grau JB; Branchetti E; Poggio P; Seefried WF; Field BC; Acker MA; Gorman RC; Gorman JH; Hargrove CW; Bavaria JE; Ferrari G
J Cell Physiol; 2012 Jun; 227(6):2595-604. PubMed ID: 22105615
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-β1 promotes fibrosis but attenuates calcification of valvular tissue applied as a three-dimensional calcific aortic valve disease model.
Jenke A; Kistner J; Saradar S; Chekhoeva A; Yazdanyar M; Bergmann AK; Rötepohl MV; Lichtenberg A; Akhyari P
Am J Physiol Heart Circ Physiol; 2020 Nov; 319(5):H1123-H1141. PubMed ID: 32986963
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and transforming growth factor-β (TGF-β) in advanced canine myxomatous mitral valve disease.
Moesgaard SG; Aupperle H; Rajamäki MM; Falk T; Rasmussen CE; Zois NE; Olsen LH
Res Vet Sci; 2014 Dec; 97(3):560-7. PubMed ID: 25458505
[TBL] [Abstract][Full Text] [Related]
16. Survival of activated myofibroblasts in canine myxomatous mitral valve disease and the role of apoptosis.
Blake RR; Markby GR; Culshaw GJ; Martinez-Pereira Y; Lu CC; Corcoran BM
Res Vet Sci; 2020 Feb; 128():99-106. PubMed ID: 31765842
[TBL] [Abstract][Full Text] [Related]
17. Emerging pathogenic mechanisms in human myxomatous mitral valve: lessons from past and novel data.
Hulin A; Deroanne C; Lambert C; Defraigne JO; Nusgens B; Radermecker M; Colige A
Cardiovasc Pathol; 2013; 22(4):245-50. PubMed ID: 23261354
[TBL] [Abstract][Full Text] [Related]
18. Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease.
Garcia-Pena A; Ibarrola J; Navarro A; Sadaba A; Tiraplegui C; Garaikoetxea M; Arrieta V; Matilla L; Fernández-Celis A; Sadaba R; Alvarez V; Gainza A; Jover E; López-Andrés N
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669101
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of Circulating Monocytes Ameliorates the Progression of Myxomatous Valve Degeneration in Marfan Syndrome.
Kim AJ; Xu N; Umeyama K; Hulin A; Ponny SR; Vagnozzi RJ; Green EA; Hanson P; McManus BM; Nagashima H; Yutzey KE
Circulation; 2020 Jan; 141(2):132-146. PubMed ID: 31928435
[TBL] [Abstract][Full Text] [Related]
20. The Role of Transforming Growth Factor-β Signaling in Myxomatous Mitral Valve Degeneration.
Tang Q; McNair AJ; Phadwal K; Macrae VE; Corcoran BM
Front Cardiovasc Med; 2022; 9():872288. PubMed ID: 35656405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
